Regular Article

British Journal of Cancer (2000) 83, 1412–1417. doi:10.1054/bjoc.2000.1477 www.bjcancer.com
Published online 14 November 2000

The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer

A Nicolini1, A Carpi2, P Ferrari1, L Anselmi1, C Spinelli2, M Conte2 and P Miccoli2

  1. 1Department of Internal Medicine, University of Pisa, Pisa, Italy
  2. 2Department of Reproduction and Aging, University of Pisa, Pisa, Italy
  3. 3Department of General Surgery, University of Pisa, Pisa, Italy

Received 19 April 2000; Revised 25 July 2000; Accepted 9 August 2000.

Top

Abstract

The aim of this retrospective study was to assess the value of a serum tumour marker panel in selecting from among the patients with equivocal chest X-ray (CXR) or liver echography (LE) those with thoracic or liver metastases respectively. Between January 1984 and December 1999, 467 (341 non-relapsed and 126 metastatic) breast cancer patients were followed-up postoperatively. Among the 126 metastatic patients 36 showed thoracic (19 patients) or liver (17 patients) metastases, alone or in conjunction with other organs as the first evidence of distant spread. We focused on this series of 377 patients including 341 non-relapsed plus 36 with liver or thoracic metastases. The patients were followed-up after mastectomy with serial determinations of a panel of CEA-TPA-CA15.3 tumour markers, bone scintigraphy, CXR and LE. Up to December 1999, equivocal CXR occurred in 23 (6.1%) patients of whom 11 (47.8%) developed thoracic metastases; 14 (3.7%) patients showed an equivocal LE of whom 5 developed liver metastases. In the 37 patients with equivocal CXR or equivocal LE prolonged clinical and imaging follow-up over 41 plusminus 36 months (mean plusminus SD, range 3–163) was used to ascertain the presence or absence of thoracic or liver metastases. In the 23 patients with equivocal CXR the negative and positive predictive values of the tumour marker panel to predict thoracic metastases were 92% and 100% respectively. In the 14 patients with equivocal LE the negative and positive predictive values of the tumour marker panel for prediction of liver metastases were 90% and 100% respectively. This study shows that in breast cancer patients the CEA-TPA-CA15.3 tumour marker panel has a high value for selecting those patients at high risk of developing clinically evident pulmonary or liver metastases from amongst those subjects with equivocal CXR or equivocal LE. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords:

breast cancer, tumour markers, equivocal chest X-ray, equivocal liver echography

Top

References

  1. ASCO Special Article (1996 Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843–2877 | ISI |
  2. Ciatto S and Herd-Smith A (1983 The role of chest x-ray in the follow-up of primary breast cancer. Tumori 69: 151–154
  3. Fargnoli R, Carrieri G and Nizzi Grifi D (1999 Torace: patologia polmonare e pleurica. DalPozzo GTomografia computerizzata e TC spirale, Utet: Torino519–592
  4. Fogelman I (1991 Bone scanning. Maisey MN, Britton KE, Gilday DL (eds) Clinical Nuclear Medicine, Chapman and Hall Medical: London pp 131–157
  5. Horton J (1984 Follow-up of breast cancer patients. Cancer 53: 790–797
  6. Kruskal JB and Kane RA (1992 Correlative imaging of malignant liver tumors. Semin Ultrasound CT MR 13: 336–354
  7. Logager VB, Vestergaard A, Herrstedt J, Thomsen HS, Zedeler K and Dombernowsky P (1990 The limited value of routine chest X-ray in the follow-up of stage II breast cancer. Eur J Cancer 26: 553–555
  8. Loomer L, Brockschmidt JK, Muss HB and Saylor G (1991 Post-operative follow-up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature. Cancer 67: 55–60
  9. Muss HB, McNamara MJ and Connelly RA (1988 Follow-up after stage II breast cancer: A comparative study of relapsed versus non relapsed patients. Am J Clin Oncol 11: 451–455
  10. Neville AM, Patel S, Capp M, Laurence DJ, Cooper EH, Turberville C and Coombes RC (1978 The monitoring role of plasma CEA alone and in association with other tumour markers in colorectal and mammary carcinoma. Cancer 42: 1448–1451
  11. Nicolini A and Carpi A (2000 postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumor Biol 21: 235–248
  12. Nicolini A, Carpi A, Di Marco G, Giuliani L, Giordani R and Palla S (1989 A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. Cancer 63: 2037–2046
  13. Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L (1991a Evaluation of serum CA15.3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64: 154–158
  14. Nicolini A, Carpi A and Tibaldi C (1991b The postoperative management of breast cancer patient: new concepts. Carpi A, Sagripanti A, Mittermayer CH (eds), pp 187–203, Sympomed Medical Publisher: MunchenProgress in Clinical Oncology,
  15. Nicolini A, Anselmi L, Michelassi C and Carpi A (1997 Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 76: 1106–1111 | PubMed |
  16. Nicolini A, Ferrari P, Sagripanti A and Carpi A (1999 The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer 79: 1443–1447 | Article |
  17. Pandya KJ, McFadden ET, Kalish LA, Tormey DC, Taylor SG 4th and Falkson J (1985 A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer 55: 202–205
  18. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P and Distante V (1994 Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271: 1593–1597 | Article | PubMed | ChemPort |
  19. Schapira DV and Urban N (1991 A minimalist policy for breast cancer surveillance. JAMA 265: 380–382 | Article | PubMed | ISI | ChemPort |
  20. Schlegel G, Luthgens M, Eklund G and Bjorklund B (1981 Correlation between activity in breast cancer and CEA, TPA and eighteen common laboratory procedures and the improvement by the combined use of CEA and TPA. Tumor Diagn 2: 6–11
  21. The GIVIO Investigators (1994 Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 271: 1587–1592 | ISI |
  22. Winchester DP, Sener SF, Khandeskar JD, Oviedo MA, Cunningham MP, Caprini JA, Burkett FE and Scanlon EF (1979 Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 43: 956–960